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Abstract: Background
Chronic musculoskeletal pain is the leading cause of disability worldwide.  The
effectiveness of pharmacological treatments for chronic pain is often limited and there
is growing concern about adverse effects, including opioid dependence. Non-
pharmacological approaches to chronic pain may be an attractive alternative or
adjunctive treatment.  We describe the effectiveness of a novel, theoretically-based,
group pain management support intervention for chronic musculoskeletal pain.
Methods and findings
We conducted a multi-centre, pragmatic, randomized controlled effectiveness and
cost-effectiveness (cost utility) trial across 27 general practices and community
musculoskeletal services in the UK.  We recruited 703 adults with musculoskeletal pain
of at least 3 months duration between August 2011 and July 2012 and randomized,
1.33:1, to intervention (403) or control (300). Intervention participants were offered a
participative, group intervention (COPERS) delivered over 3 alternate days with a
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
follow up session at 2 weeks.  The intervention introduced cognitive behavioural
approaches and was designed to promote self-efficacy to manage chronic pain.
Controls received usual care and a relaxation CD.  The primary outcome was pain
related disability at 12 months (Chronic Pain Grade, CPG, disability subscale);
secondary outcomes, measured at 6 and 12 months, included: Hospital Anxiety and
Depression Scale (HADS) scores, Chronic Pain Acceptance Questionnaire; Health
education impact Questionnaire Social integration subscale; Pain Self-Efficacy
Questionnaire; pain intensity (CPG subscale), the Census global health question,
health utility (EQ-5D-3L) and healthcare resource use. Analyses followed intention to
treat principles, accounted for clustering by course in the intervention arm, and used
multiple imputation for missing, or incomplete, primary outcome data.
The mean age of participants was 59.9 years with:  81% white, 67% female, 23% in
employment, 85% with pain for at least three years, 23% on strong opioids. Symptoms
of depression and anxiety were common (baseline mean HADS scores 7.4 (SD 4.1)
and 9.2 (4.6), respectively). Overall 282 (70%) intervention participants met the pre-
defined intervention adherence criterion.  Primary outcome data were obtained from
88% of participants.  There was no significant difference between groups in: pain
related disability at six or 12 months (12 months: difference -1.0, intervention vs.
control, 95% CI -4.9 to 3.0); pain intensity; or the global health question.  Anxiety,
depression, pain self-efficacy, pain acceptance and social integration were better in the
intervention group at six months; at 12 months these differences only remained
statistically significant for depression  (-0.7, 95% CI -1.2 to -0.2) and social integration
(0.8, 95% CI 10.4 to 1.2). Intervention participants received more analgesics than the
controls across 12 months. The total cost of the course per person was £145 ($214).
The cost utility analysis showed there to be a small benefit in terms of QALYs (0.0325,
95% CI: -0.0074 to 0.0724), and on the cost side the intervention was a little more
expensive (i.e. £188 ($277), 95% CI -£125 (-$184) to £501 ($738)), resulting in an
ICER of £5,786 ($8,521) per QALY.  Limitations include the fact that the intervention
was relatively brief and did not include any physical activity components.
Conclusions
While the COPERS intervention is brief, safe and inexpensive with a low attrition rate, it
was not effective for reducing pain related disability over 12 months (primary outcome).
For secondary outcomes, we found sustained benefits on depression and social
integration at 6 and 12 months, but there was no effect on anxiety, pain-related self-
efficacy, pain acceptance, pain intensity or the census global health question at 12
months. There was some evidence that the intervention may be cost-effective based
on a modest benefit on QALYs between groups.
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trials.com/isrctn/
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ABSTRACT 
Background  
Chronic musculoskeletal pain is the leading cause of disability worldwide.  The effectiveness of 
pharmacological treatments for chronic pain is often limited and there is growing concern about adverse 
effects, including opioid dependence. Non-pharmacological approaches to chronic pain may be an attractive 
alternative or adjunctive treatment.  We describe the effectiveness of a novel, theoretically-based, group 
pain management support intervention for chronic musculoskeletal pain.  
 
Methods and findings  
We conducted a multi-centre, pragmatic, randomized controlled effectiveness and cost-effectiveness (cost 
utility) trial across 27 general practices and community musculoskeletal services in the UK.  We recruited 703 
adults with musculoskeletal pain of at least 3 months duration between August 2011 and July 2012 and 
randomized, 1.33:1, to intervention (403) or control (300). Intervention participants were offered a 
participative, group intervention (COPERS) delivered over 3 alternate days with a follow up session at 2 
weeks.  The intervention introduced cognitive behavioural approaches and was designed to promote self-
efficacy to manage chronic pain.  Controls received usual care and a relaxation CD.  The primary outcome 
was pain related disability at 12 months (Chronic Pain Grade, CPG, disability subscale); secondary outcomes, 
measured at 6 and 12 months, included: Hospital Anxiety and Depression Scale (HADS) scores, Chronic Pain 
Acceptance Questionnaire; Health education impact Questionnaire Social integration subscale; Pain Self-
Efficacy Questionnaire; pain intensity (CPG subscale), the Census global health question, health utility (EQ-
5D-3L) and healthcare resource use. Analyses followed intention to treat principles, accounted for clustering 
by course in the intervention arm, and used multiple imputation for missing, or incomplete, primary 
outcome data. 
 
The mean age of participants was 59.9 years with:  81% white, 67% female, 23% in employment, 85% with 
pain for at least three years, 23% on strong opioids. Symptoms of depression and anxiety were common 
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(baseline mean HADS scores 7.4 (SD 4.1) and 9.2 (4.6), respectively). Overall 282 (70%) intervention 
participants met the pre-defined intervention adherence criterion.  Primary outcome data were obtained 
from 88% of participants.  There was no significant difference between groups in: pain related disability at six 
or 12 months (12 months: difference -1.0, intervention vs. control, 95% CI -4.9 to 3.0); pain intensity; or the 
global health question.  Anxiety, depression, pain self-efficacy, pain acceptance and social integration were 
better in the intervention group at six months; at 12 months these differences only remained statistically 
significant for depression  (-0.7, 95% CI -1.2 to -0.2) and social integration (0.8, 95% CI 10.4 to 1.2). 
Intervention participants received more analgesics than the controls across 12 months. The total cost of the 
course per person was £145 ($214). The cost utility analysis showed there to be a small benefit in terms of 
QALYs (0.0325, 95% CI: -0.0074 to 0.0724), and on the cost side the intervention was a little more expensive 
(i.e. £188 ($277), 95% CI -£125 (-$184) to £501 ($738)), resulting in an ICER of £5,786 ($8,521) per QALY.  
Limitations include the fact that the intervention was relatively brief and did not include any physical activity 
components. 
Conclusions  
While the COPERS intervention is brief, safe and inexpensive with a low attrition rate, it was not effective for 
reducing pain related disability over 12 months (primary outcome). For secondary outcomes, we found 
sustained benefits on depression and social integration at 6 and 12 months, but there was no effect on 
anxiety, pain-related self-efficacy, pain acceptance, pain intensity or the census global health question at 12 
months. There was some evidence that the intervention may be cost-effective based on a modest benefit on 
QALYs between groups. 
 
Trial registration   International Standard Randomised Controlled Trial Number Register (ISRCTN) 
registration number 24426731, http://www.controlled-trials.com/isrctn/ 
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Author Summary 
 
Why Was This Study Done?  
Chronic pain, of which chronic musculoskeletal pain is a major component, is one of the most important 
causes of disability worldwide.  
Pharmacological interventions are ineffective, or only partially effective, for many people with chronic 
pain and there is increasing concern about side effects (for example with non-steroidal anti-
inflammatory drugs) or drug dependence (with opioids or the gabapentinoids). 
After systematically reviewing the evidence we developed “COPERS” - a novel, brief, psychologically 
based, group intervention directed at increasing participants’ confidence and their repertoire of skills 
around managing pain. 
Our aim was to reduce participants’ pain related disability.  
What Did the Researchers Do and Find?  
We conducted a large randomized control trial of the intervention; 703 participants, mostly identified 
from primary care, were randomized in a ratio of  1.33:1, to receive either the new intervention or 
usual care and a relaxation CD.   
We followed up participants from baseline (before they were allocated to a study arm)  for 12 months  
and measured their pain related disability (our primary outcome) and a number of other secondary  
outcomes,  including anxiety and depression and  the amount of health care resources they used 
across the 12 months.  
The average age of the study participants was  60 years, few were in work and most (85%) had had pain 
for at least three years;  overall at baseline they reported poor health and high levels of pain related 
disability, nearly a quarter (23%) were being prescribed strong opioids.  
The intervention had no effect on our primary outcome, pain related disability, at six or 12 months 
follow up.   The psychological outcomes were better in the group receiving the intervention 
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compared to the usual care group at six months, but by 12 months only depression and social 
integration remained improved.  
What Do These Findings Mean?  
This study suggests that brief, group based psychological interventions are insufficient to improve pain 
related disability in with people with long-established, chronic musculoskeletal pain and alternative 
treatments are needed.  
Anxiety and depression are common in people who have chronic pain and the study holds out the 
tantalising prospect that the new intervention could improve their psychological well-being, but 
further research is needed before this conclusion can be firmly drawn.   
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Introduction 1 
Chronic pain is common, affecting an estimated 20% [1] to 30% [2] of adults worldwide.  It is associated with 2 
disability, psychological co-morbidity, reduced quality of life, early mortality and high healthcare costs. The 3 
burden of disability due to chronic musculoskeletal disorders, commonly associated with chronic pain, 4 
increased worldwide by 46% between 1990 and 2010, with further increases predicted in coming years due 5 
to aging populations and increasing obesity [3]. In 2013 musculoskeletal disorders (combined with fractures 6 
and soft tissue injuries) accounted for over 20% of years lived with a disability across the globe [4].  Low back 7 
pain alone is the leading cause of disability in 86 countries and the second or third leading cause of disability 8 
in a further 67 countries [4]. 9 
 10 
Although pharmacological therapies have an important role in chronic pain, their effectiveness is often 11 
limited [5] and there is considerable concern about the adverse effects of non-steroidal anti-inflammatory 12 
drugs [6,7]. Many patients with chronic pain receive opioids, despite a lack of evidence around their long 13 
term effectiveness [8] and the risk of side-effects,  including dependence [9].Non-pharmacological 14 
approaches to chronic pain, such as pain management and self-management support courses that aim to 15 
improve quality of life and encourage positive behaviour change, may be an attractive alternative. There are, 16 
however, limited data to support their use. There is evidence suggesting that improving self-efficacy (an 17 
individual’s belief in their ability to succeed in a particular situation) may be a key mechanism for 18 
improvement in other outcomes [10,11] placing self-efficacy as a focus of interest for self-management 19 
interventions [12]. 20 
 21 
Based on a systematic review analysing the literature on the characteristics and effectiveness of pain 22 
management programmes [13], we developed a novel, theoretically underpinned, self-management support 23 
programme to improve the management of chronic musculoskeletal pain in the community and conducted a 24 
trial of this intervention: Coping with persistent Pain, Effectiveness Research into Self-management study 25 
(COPERS) [14]. This programme aimed to increase self-efficacy to manage chronic pain and attempted to 26 
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address the social isolation which may accompany the experience of living with chronic pain [14]. We 27 
conceptualised the intervention within the ‘three-process model of pain’ [15], which focuses on physiological 28 
processes, subjective-affective-cognitive processes, and behavioural processes. In this model these are non-29 
discrete, interactive processes. Hence our intervention relied on changes in understanding, mood and 30 
behaviour to enhance pain-related self-efficacy, which in turn would interact to reinforce new behaviours 31 
and impact on outcomes. We hypothesised that this new intervention would reduce pain related disability in 32 
people with chronic musculoskeletal pain. Here we describe a randomised controlled trial testing the 33 
effectiveness and cost effectiveness of the COPERS programme.  34 
Ethics Statement: 35 
The trial was overseen by independent Trial Steering and Data Monitoring and Ethics committees. Ethical 36 
approval was granted by Cambridgeshire Ethics Committee Ref: 11/EE/046.  37 
 38 
Methods 39 
 40 
Study participants 41 
We conducted a pragmatic, multi-centre, randomised controlled trial of the ‘COPERS’ group self-42 
management course for adults living with chronic musculoskeletal pain. Causes of pain included, but were 43 
not restricted to, osteoarthritis, back pain, chronic widespread pain and fibromyalgia. Participants were 44 
recruited in the UK (London and the Midlands) from primary care, community musculoskeletal pain services 45 
and secondary care pain services.  The trial protocol and statistical analysis plan have been published 46 
previously [16,17]. 47 
 48 
Between August 2011 and July 2012 Potential participants were identified via electronic patient record 49 
searches [18], face to face consultation, and advertisements in clinic areas. Those who responded to initial 50 
approaches or advertisement were sent a screening questionnaire. Eligibility was subsequently confirmed in 51 
a telephone interview with a researcher, who then sent potential participants a baseline questionnaire and 52 
consent form. We included adults (aged ≥ 18 years) with musculoskeletal pain of at least three months 53 
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duration [19]. Exclusion criteria were: inability to give informed consent; not fluent in English; chronic pain 54 
arising from active malignant disease or inflammatory arthritis; terminal illness; or such serious uncontrolled 55 
mental health or substance abuse issues that it would be difficult for the individual to participate in the 56 
group sessions (this was determined by the participant’s general (family) practitioner (GP) following the 57 
electronic patient searches or at discussion between participant and researcher at the telephone interview). 58 
The trial was overseen by independent Trial Steering and Data Monitoring and Ethics committees (See 59 
Section 1 of S1 Appendix). Ethical approval was granted by Cambridgeshire Ethics Committee Ref: 60 
11/EE/046.  61 
 62 
Randomisation 63 
Following the return of completed baseline questionnaires, participants were randomised to the two groups 64 
in a 1.33 to 1 ratio in favour of the intervention arm. Strict allocation concealment was maintained via an 65 
independent, centralised, online service which used stratified permuted blocks with randomly varying block 66 
sizes of 7 or 14 and recruitment site as a stratification factor.  67 
 68 
Outcome Measures 69 
Participants completed postal questionnaires containing the outcome measures before randomisation and 70 
at six and 12 months following randomisation. If necessary we collected primary outcomes by phone. 71 
Selection of outcome measures was based on their clinimetric qualities and informed by patient 72 
consultation. The primary outcome was pain related disability at 12 months. We chose a well-validated tool, 73 
the Chronic Pain Grade (CPG) which has two constructs—pain intensity and pain-related disability, which are 74 
scored independently and can be combined to form the Chronic Pain Grade [20]. Each construct has been 75 
validated separately [21]. The three disability subscale questions ask about pain interference with daily 76 
activities, change in ability to take part in recreational, social and family activities, and change in ability to 77 
work (including housework) over the past six months [20,21]. To generate the outcome each item is scored 78 
on a scale 0-10 (worst) and the mean is taken and multiplied by 100. This outcome has been used in a 79 
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number of other trials investigating long term pain [22,23]. Secondary outcomes were: the CPG pain 80 
intensity subscale [20,21], the census global health question [24], anxiety and depression (Hospital Anxiety 81 
and Depression Scale, HADS) [25], the Chronic Pain Acceptance Questionnaire (CPAQ) [26], the Health 82 
Education Impact Questionnaire (heiQ) Social integration and support subscale [27], health utility EQ-5D-3L 83 
[28], the Pain Self-Efficacy Questionnaire (PSEQ) [29]and health care resource use. We also examined use of 84 
psychotropic medicines, analgesics and weak and strong opioids by looking at total World Health 85 
Organisation defined daily doses (DDDs) of selected medications prescribed in the 12 months following 86 
randomisation and the proportion of participants using strong and weak opioids at 12 months follow up, full 87 
details of our outcome measures and methods are described in Sections 2, 3 and 4 of S1 Appendix. Due to 88 
the nature of the intervention, it was not feasible to mask participants or group facilitators to study arm. 89 
Participants’ healthcare professionals and all those retrieving, handling or processing outcome data 90 
remained unaware of participants’ allocated study arms.  91 
 92 
Adverse events for both arms were collected following standard operation procedures for the Pragmatic 93 
Clinical Trials Unit and our adverse events protocol. Adverse events in the control arm could be reported by 94 
participants at any time via phone or post and we also collected all medical records at the end of the study. 95 
All deaths occurring during the study period were scrutinised to determine if they were related to the study. 96 
 97 
Intervention 98 
The intervention was a group facilitated, experiential learning course based on cognitive behavioural 99 
principles plus usual care (Table 1); its development and content is described in detail elsewhere [14]. 100 
Briefly, the course consisted of 24 individual components delivered in a community setting over three 101 
alternate days in one week with a follow-up session two weeks later (total duration = 14 hours).  Content 102 
included: cognitive behavioural approaches to managing chronic pain (these covered: acceptance, attention 103 
control, goal setting and action planning, recognising unhelpful thinking and behaviours); an educational 104 
DVD with a pain consultant answering common questions from a patient with chronic pain; communication 105 
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skills; relationships; hobbies and activities; posture and movement; breathing, relaxation and guided 106 
imagery. Courses were delivered by two facilitators: a health care professional with experience of treating 107 
people with chronic musculoskeletal pain (physiotherapist, psychologist, osteopath, or GP) and a lay person 108 
living with chronic pain.  Following a two day joint training programme, facilitators who met pre-determined 109 
competence criteria were selected to deliver the intervention. All courses were audio recorded and a 110 
random selection of the recordings of particular components from each course was analysed to evaluate 111 
intervention fidelity, described in detail elsewhere [30]. Participants present for at least 17 of the 24 course 112 
components were deemed ‘adherent’ to the intervention according to pre-determined criterion. 113 
 
Table 1 Outline of the intervention – The COPERS course 
Day Modules Content  of sessions 
1 
Living and 
dealing with pain 
1. Introduction and 
Understanding pain and 
acceptance 
Session 1: Introduction 
Session 2: Pain information   
Session 3: Acceptance:  The uninvited guest 
Lunch 
Taster activity – Art 
2. Mind, mood and pain Session 4: Pain, when is it bearable and when is it not?  
Session 5: The pain cycle  
3. Movement and 
Relaxation  
Session 6: Posture 
Session 7: Relaxation and breathing 
2  
Doing something 
about your life 
with pain 
4. Dealing with unhelpful, 
negative thoughts and 
barriers to change 
Session 8: Reflections from day one   
Session 9: Identifying problems, goal setting and action 
planning 
Session 10: Barriers to change - unhelpful thinking  
Lunch 
Taster activity – Hand massage 
5. Making pain more 
manageable 
Session 11: Barriers to change – reframing negatives to 
positives 
 Session 12: Attention control and distraction 
Session 13: Things that make pain more manageable 
6. Movement and 
Relaxation 
Session 14: Balance and stretch 
Session 15: Relaxation and visualisation 
3 
Communication 
and relationships 
 
7. Communication skills Session 16: Reflections from day 2 
Session 17: Communicating with your GP  
Session 18: Listening skills  
Session 19: Anger, irritability and frustration 
Lunch 
Taster activity – Volunteering 
8. Movement and 
Relaxation 
Session 20: Stretch 
Session 21: Relaxation and mindfulness of thoughts 
Session 22. Summary of the course 
4  
Follow up 
9. The future Session 23: Reflections and feedback from the group 
Session 24: Managing setbacks 
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Usual care  114 
The control group received usual care, including a widely available pain education leaflet 115 
(http://www.paintoolkit.org/downloads/SC_TK_NHS_TAYSIDE.pdf), and a relaxation CD (also given to 116 
intervention participants). To mimic the duration of the intervention, control participants were asked to 117 
practise relaxation daily for three weeks and whenever they wished thereafter. 118 
 119 
Statistical Analyses  120 
To show a standardised mean difference (mean difference divided by the standard deviation at baseline) in 121 
pain related disability of 0.3 between intervention and control groups, at a 5% significance level with 80% 122 
power, would require data from 350 participants.  To minimise the overall sample size in a situation where 123 
clustering occurred only in the intervention arm (due to the group intervention), we used Moerbeek’s 124 
method, inflating the sample size by 1.37 (assuming an intra-cluster correlation coefficient of 0.1 and nine 125 
participants per course providing 12 month follow-up data) and using an unbalanced randomisation (1.33:1 126 
in favour of the intervention) [31].We required data from 480 individuals. Allowing for a 30% loss to follow-127 
up we sought to randomise 685 participants (391:294). 128 
 129 
All analyses were performed according to the intention-to-treat principle. All participants with an available 130 
outcome were analysed according to the group to which they were randomised. All analyses accounted for 131 
clustering by course in the intervention arm through use of a random-effect in a mixed-effects regression 132 
model (with participants in the control arm acting as their own cluster) [32]. Treatment group, age, gender, 133 
site of recruitment (London or Midlands)[33-35], and baseline level of outcome were included in each 134 
analysis as fixed effects [36]. 135 
 136 
We used multiple imputation for analysis of the primary outcome of pain related disability [34]. We imputed 137 
the individual questions that formed the CPG disability score, and therefore included in the imputation 138 
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model and in the analysis all participants who answered at least one question on the CPG disability subscale 139 
at either 6 or 12 months. Participants who did not answer any questions on the CPG subscale at either 6 or 140 
12 months were excluded from the analysis. We used multilevel imputation, with course included in the 141 
imputation model as a random effect. The imputation model included the three questions that formed the 142 
CPG disability score at baseline, 6 and 12 months, as well as site of recruitment, age, gender, HADS 143 
depression score at baseline, and employment status. Imputation was conducted separately within each 144 
treatment group, and 20 imputations were performed (i.e. we created 20 complete datasets). We analysed 145 
outcomes at 6 and 12 months separately, using a mixed-effects linear regression model as described above. 146 
Results were combined using Rubin’s rules [37] Analysis of secondary outcomes is described in Section 4 of 147 
S1 Appendix. 148 
 149 
We performed sensitivity analyses to assess robustness to different assumptions regarding the missing data 150 
(methods described in Section 5 of S1 Appendix). We performed the following pre-planned subgroup 151 
analyses for the primary outcome (full details in Section 11 of S1 Appendix): number of co-morbidities, living 152 
arrangements, baseline PSEQ score, socioeconomic status, pain duration, baseline CPG pain intensity score, 153 
baseline CPG disability score, and baseline HADS depression score. Subgroup analyses were performed by 154 
including an interaction between the specified subgroup and treatment arm in the analysis. Full details of 155 
the statistical methods can be found in the analysis plan (including details for all subgroup analyses, 156 
sensitivity analyses, and analyses of secondary outcomes) [17], which was finalised before any investigators 157 
had unmasked access to trial data. All analyses presented here were predefined in the statistical analysis 158 
plan [17] unless otherwise stated. A list of deviations from the analysis plan is available in Section 6 of S1 159 
Appendix. Analysis was performed using Stata v13 and REALCOM [38]. 160 
 161 
Health economic analysis  162 
The health economic analysis took a health-care provider perspective and estimated the costs of delivering 163 
the intervention and all further primary, secondary and community care costs (see Section 7 of S1 Appendix 164 
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for more detail on methods). Service use data, including all prescribing data, were collected from 165 
participants’ GP electronic records at 12 months follow-up. Data relating to secondary care use over was 166 
downloaded from the Secondary Uses Services database [39]. Resource use data were combined with unit 167 
costs to calculate the total cost of health service use for each participant (see Section 8 of S1 Appendix for 168 
unit costs). Missing data for costs and Quality Adjusted Live Years (QALYs) were imputed using Stata 169 
12.1.The primary economic analysis was a cost-utility analysis over 12 months using QALYs calculated from 170 
the EQ-5D-3L. We used a mixed-effects linear regression model to adjust estimates of costs and QALYs for: 171 
baseline measures, treatment group, age, gender, and site of recruitment as fixed effects and course as a 172 
random effect (with participants in the control arm acting as their own cluster).  We used the non-173 
parametric bootstrap and multiple imputations to compute cost-effectiveness acceptability curves and 174 
assessed cost-utility using willingness to pay thresholds ranging between £0 and £30,000 ($44,183). Costs 175 
were converted to US Dollars using purchasing power parity rate (2013) (http://stats.oecd.org/). 176 
 177 
Results  178 
Study participants 179 
Between August 1, 2011 and July 31, 2012 we randomised 703 participants from 35 general practices, two 180 
secondary care pain services and one community based musculoskeletal service (403:300, intervention: 181 
control)  (Fig I).  182 
--------------------------Insert Fig 1  COPERS Consort Flow chart here-------------------------------------- 183 
 184 
We over recruited to ensure the final self-management support groups at all study centres achieved the pre-185 
specified minimum number of attending participants (five). Intervention and control participants were well 186 
matched at baseline (Table 2). Most of the participants (85%) had had pain for at least three years with 265 187 
(38%) reporting pain for more than ten years and 162 (23%) being prescribed strong opioids (as defined in 188 
the British National Formulary [40]) at baseline. The median number of co-morbidities (determined from 189 
primary care records) was two (range 0-8). Only 169 (24%) were in any form of employment, with 148 (21%) 190 
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unable to work due to long term sickness and another 307 (44%) who were retired. Overall health utility as 191 
assessed by the EQ-5D-3L (commonly interpreted as quality of life) was very low (mean 0.4, SD 0.34). 192 
 193 
Eleven health care professionals and 13 lay people delivered 35 courses (the mean number of participants 194 
per course was 14). The mean waiting time from randomisation to attending a course was six weeks (range 195 
0-24 weeks); 67/403 (17%) intervention participants did not attend a course, and 282 (70%) met our pre-196 
defined definition of adherence.  197 
Table 2 Baseline characteristics 
 
Control 
n=300 
Number (%) 
unless indicated 
otherwise 
Intervention 
n=403 
Number (%) 
unless indicated 
otherwise 
Number of 
Participants 
with missing 
data 
(control, 
intervention) 
Age (years) – mean (SD) 59.4 (13.8) 60.3 (13.5) 0, 0 
Male  98 (33) 132 (33) 0, 0 
Lives alone  101 (34) 143 (36) 4, 6 
Ethnicity    0, 0 
     White 239 (80) 325 (81) - 
     Black 36 (12) 53 (13) - 
     Asian 20 (7) 13 (3) - 
     Mixed/other 5 (<1) 12 (3) - 
Age at which formal education ended    0, 0 
     16 years old or less 157 (52) 224 (56) - 
     20 years old or later 135 (45) 173 (43) - 
     Other 8 (3) 6 (1) - 
Employment status    0, 0 
     Employed, including self-employed (full 
or part time)a 
95 (32) 115 (29) - 
Unemployed looking for work or unable due 
to long term sickness 
72 (24) 106 (26) - 
15 
 
 
Control 
n=300 
Number (%) 
unless indicated 
otherwise 
Intervention 
n=403 
Number (%) 
unless indicated 
otherwise 
Number of 
Participants 
with missing 
data 
(control, 
intervention) 
     Retired from paid work 132 (44) 175 (43) - 
     Other 1 (<1) 7 (2) - 
Time kept from usual activities due to pain 
in past 6 months 
  3, 3 
     0-6 days 84 (28) 136 (34) - 
     7-14 days 49 (17) 72 (18) - 
     15-30 days 57 (19) 71 (18) - 
     31 or more days 107 (36) 121 (30) - 
State of healthb   0, 0 
     Very good 17 (6) 27 (7) - 
     Good 100 (33) 138 (34) - 
     Fair 130 (43) 159 (39) - 
     Bad 45 (15) 63 (16) - 
     Very Bad 8 (3) 16 (4) - 
Duration of pain    0, 0 
     0-3 months 4 (1) 1 (<1) - 
     4-12 months 10 (3) 15 (4) - 
     13 months – 2 years 43 (14) 45 (11) - 
     3-4 years 45 (15) 55 (14) - 
     5-6 years 40 (13) 49 (12) - 
     7-10 years 50 (17) 81 (20) - 
     More than 10 years 108 (36) 157 (39) - 
CPG20 overallc   3, 5 
     0 0 (0) 0 (0) - 
     1 18 (6) 30 (8) - 
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Control 
n=300 
Number (%) 
unless indicated 
otherwise 
Intervention 
n=403 
Number (%) 
unless indicated 
otherwise 
Number of 
Participants 
with missing 
data 
(control, 
intervention) 
     2 66 (22) 99 (25) - 
     3 81 (27) 123 (31) - 
     4 132 (44) 146 (37) - 
CPG20 disabilityd – mean (SD) 63.8 (24.4) 62.9 (25.7) 0, 1 
CPG20 pain intensitye – mean (SD) 70.9 (15.3) 71.5 (17.0) 1, 1 
PSEQ29,f – mean (SD) 30.6 (14.1) 31.2 (13.8) 0, 5 
CPAQ26, g – mean (SD) 55.3 (19.1) 57.5 (20.7) 7, 15 
HADS depression25, h – mean (SD) 7.5 (4.0) 7.4 (4.2) 3, 2 
HADS anxiety25, i – mean (SD) 9.3 (4.7) 9.2 (4.6) 3, 3 
HADS25 depression score categories   3, 2 
0 – 7 (normal) 159 (54) 217 (54)  
8 – 10 (mild) 74 (25) 95 (24)  
11 – 21(moderate or severe) 64 (22) 89 (22)  
Health education impact questionnaire 
(heiQ)27Social integration and support 
subscalej– mean (SD) 
13.8 (3.4) 14.0 (3.6) 5, 3 
EQ-5D-3L28,k– mean (SD) 0.39 (0.34) 0.41 (0.34) 1, 1 
Number of co-morbiditiesl – median (IQR) 3 (2 to 4) 2 (2 to 3) 21, 32 
a Includes in full time education and looking after home/ family  bUK Census general health question24,  
cCPG Pain grades 0 (no pain)- 4(high disability, severely limiting pain);dCPG pain disability, mean CPG 
disability items scored on a scale 0-10 (worst) and multiplied by 100 thus 100 = worst possible score; 
eCPG pain intensity, mean of the three pain intensity CPG items scored on a scale 0-10 (worst)and 
multiplied by 100;  fPSEQ 0-60 (best);gCPAQ 0-120(best), hHADS depression0-21 (worst), iHADS anxiety0-
21 (worst); jHEIQ4-20 (best),kEQ5D<0-1 (best),l from primary care records. 
 
Pain related disability 198 
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We obtained a complete set of baseline and primary outcome data from 621 (88%) participants, with 199 
multiple imputation for missing primary outcome data (see above) were able to include 652 (93%) 200 
participants in our analysis (Figure 1). Table 3 shows the results for primary and secondary outcomes at six 201 
and 12 months follow-up. Pain related disability did not differ between treatment groups at either time (12 202 
months: intervention mean 52.9 (SD 28.0) vs. control mean 53.3 (SD 28.8); difference (intervention vs. 203 
control) -1.0, 95% CI -4.9 to 3.0).  204 
Table 3. Main results for primary and secondary outcomes 
 
 Controla 
(n=300) 
Interventiona 
(n=403) Treatment effectb (95% CI) 
 Mean (SD) Mean (SD) Difference in 
means 
(intervention 
minus control) 
SMDc (standardised 
mean difference) 
Chronic Pain Grade20 
CPG disability  
    
           6 months 54.3 (26.7) 53.2 (25.7) -1.2 (-4.8 to 
2.4) 
-0.06 (-0.24 to 0.12) 
          12 months 53.3 (28.8) 52.9 (28.0) -1.0 (-4.9 to 
3.0) 
-0.04 (-0.22 to 0.13) 
CPG pain intensity      
           6 months 64.3 (19.4) 65.0 (18.8) 1.0 (-1.5 to 3.6) 0.07 (-0.10 to 0.24) 
          12 months 64.4 (20.1) 63.5 (20.3) -0.9 (-3.7 to 
1.9) 
-0.06 (-0.23 to 0.12) 
Pain self-efficacy 
Questionnaire29 
PSEQ score  
    
6 months 32.7 (15.0) 35.5 (14.0) 2.3 (0.6 to 4.1) 0.25 (0.07 to 0.43) 
          12 months 33.4 (15.1) 35.4 (14.1) 1.4 (-0.2 to 3.1) 0.15 (-0.02 to 0.32) 
Hospital Anxiety 
Depression Scale25 
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 Controla 
(n=300) 
Interventiona 
(n=403) Treatment effectb (95% CI) 
HADS Anxiety score  
           6 months 9.1 (4.8) 8.2 (4.7) -0.7 (-1.3 to -
0.2) 
-0.24 (-0.41 to  
-0.06) 
 Mean (SD) Mean (SD) Difference in 
means 
(intervention 
minus control) 
SMD (standardised 
mean difference) 
          12 months 8.4 (4.5) 8.1 (4.5) -0.4 (-0.9 to 
0.1) 
-0.13 (-0.30 to 0.03) 
HADS25 Depression score      
           6 months 7.0 (4.4) 6.3 (4.1) -0.7 (-1.2 to -
0.2) 
-0.25 (-0.44 to  
-0.06) 
            12 months 6.9 (4.6) 6.2 (4.3) -0.7 (-1.2 to -
0.2) 
-0.22 (-0.39 to  
-0.06) 
Chronic Pain Acceptance 
Questionnaire26 
CPAQ score  
    
            6 months 59.2 (19.7) 64.4 (20.0) 3.4 (1.3 to 5.5) 0.27 (0.08 to 0.45) 
          12 months 74.0 (14.4) 73.1 (15.1) -0.8 (-3.0 to 
1.4) 
-0.03 (-0.20 to 0.13) 
Health education impact 
questionnaire 
(heiQ)27Social integration 
and support subscale 
    
           6 months 14.3 (3.6) 14.9 (3.3) 0.6 (0.1 to 1.0) 0.25 (0.06 to 0.43) 
          12 months 14.1 (3.6) 14.9 (3.5) 0.8 (0.4 to 1.2) 0.32 (0.16 to 0.49) 
 Mean (SD) Mean (SD) Difference in 
means 
SMD (standardised 
mean difference) 
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 Controla 
(n=300) 
Interventiona 
(n=403) Treatment effectb (95% CI) 
(intervention 
minus control) 
EQ-5D-3L28     
           6 months 0.41 (0.35) 0.46 (0.34) 0.03 (-0.01 to 
0.08) 
0.13 (-0.03 to 0.29) 
          12 months 0.45 (0.35) 0.46 (0.34) 0.00 (-0.04 to 
0.04) 
0.01 (-0.16 to 0.17) 
aMean (SD) for both treatment groups are based on raw data, i.e. are unadjusted. 
b The difference in means and the SMD were adjusted for age, gender, site of recruitment (London or Midlands), and 
baseline level of outcome.  
c SMDs were calculated using the residual SD obtained from the analysis model. 
 
Secondary outcomes 205 
 
At six months self-efficacy (PSEQ , difference 2.3, 95% CI 0.6 to 4.1), anxiety (HADS anxiety subscale, -0.7, 206 
95% CI -1.3 to -0.2), depression (HADS depression subscale, -0.7, 95% CI -1.2 to -0.2), pain acceptance (CPAQ, 207 
3.4, 95% CI 1.3 to 5.5) and social integration (heiQ, 0.6, 95% CI 0.1 to 1.0) had all improved more in the 208 
intervention group compared to the control group (Table 3). At 12 months the differences favouring the 209 
intervention were sustained for depression (-0.7, 95% CI -1.2 to -0.2) and social integration (0.8, 95% CI 0.4 210 
to 1.2). All sensitivity analyses found similar results to the primary analysis, demonstrating that primary 211 
outcome results were robust (see Section 9 of S1 Appendix for full results). 212 
 213 
There was no difference in responses to the Census global health question at 6 or 12 months follow up (odds 214 
ratio for intervention group participants being improved at 12 months was 1.07, 95% CI 0.77 to 1.51). Overall 215 
intervention patients received considerably more analgesics than controls in the 12 months following 216 
randomisation (amounting to an average difference of 98 days of medication at WHO standard dosing (95% 217 
CI 17 to 178)). They also received significantly more weak opioids (18 DDDs, 95% CI 5 to 32 days). However 218 
there was no evidence of any difference in the prescription of strong opioids between treatment arms (-1 219 
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DDD, 95% CI -12 to 11), nor in the proportions of those receiving strong opioids at 12 months (see Section 10 220 
of S1 Appendix for full results). 221 
 222 
No serious adverse events occurred with the intervention or in the control arm. Two deaths occurred during 223 
the study: one intervention patient and one control patient. Both cases were considered by the chair of our 224 
DMEC to be unrelated to the study and thus not to represent adverse events. 225 
 226 
Pre-specified sub-group analyses, examining subgroups based on number of co-morbidities, living 227 
arrangements, baseline PSEQ score, socioeconomic status, pain duration, baseline CPG pain intensity score, 228 
baseline CPG disability score, and baseline HADS depression score, found no differences across subgroups 229 
(full results in Section 11 of S1 Appendix) for the primary outcome. An exploratory post hoc sub-group 230 
analysis found that improvement in 12 month depression scores occurred only in those who were likely to 231 
be depressed at baseline (P value for interaction 0.004) (Table 4). No serious adverse events occurred with 232 
the intervention or in the control arm. 233 
Table 4 Sub-group analysis* of HADS depression score at 12 months by HADS depression score at 
baseline: 0-7 vs. 8-21 
HADS depression 
score at baseline 
Control – mean 
(SD) 
Intervention – 
mean (SD) 
Treatment effect (95% 
CI) 
P-value for 
interaction 
Original scale  
0-7 4.2 (3.0) 4.0 (3.0) 0.0 (-0.7 to 0.6) 0.004 
8-21 9.4 (4.8) 8.2 (4.7) -1.5 (-2.3 to -0.8) 
Standardised mean difference 
0-7 - - -0.01 (-0.23 to 0.21) - 
8-21 - - -0.50 (-0.74 to -0.25) 
*625 participants were included in the sub-group analysis: 348 patients with HADS depression score 0-7 (148 usual care, 200 
intervention), and 277 patients with HADS depression score 8-21 (113 usual care, 164 intervention). 
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Health economic analyses 234 
We obtained complete health economics data from 540 participants (77%) of participants. The highest 235 
proportion of missing data was for baseline prescriptions, followed by EQ-5D-3L and primary care contacts. 236 
Imputing the data for missing values resulted in a data set of 647 participants (92%) (control n=275, 237 
intervention n=372), which represented 99% of the trial population included in the statistical analyses of the 238 
primary outcome. The cost of delivering courses, including the cost of training the facilitators was £145 239 
($214) per person. Total costs were higher in the intervention group (£2,955, $4,352) compared to the 240 
control group (£2,767, $4,075) and the difference in means was £188 ($277), 95% CI -£125 (-$184) to £501 241 
($738). Total QALYs were also higher in the intervention group (0.4475) compared to the control group 242 
(0.4150) and the difference in the means was 0.0325 (95%CI -0.0074; 0.0724) QALYs. The ICER mean point 243 
estimate was £5,786 ($8,521) per QALY. The intervention had a high probability (87%) of being cost-effective 244 
at a willingness to pay of £30,000 ($44,183) per QALY. Results of cost-effectiveness analyses are shown in 245 
Section 12 of S1 Appendix. 246 
 247 
Discussion 248 
Our chronic pain self-management intervention (COPERS) was relatively cheap to deliver, and had a good 249 
uptake (336/403, 86%) with little attrition. We found no evidence of impact on our primary outcome of pain 250 
related disability at 12 months, or at six months. However at six months the COPERS intervention led to 251 
improved psychological well-being compared to the control group with regard to all our psychological 252 
measures - anxiety, depression, chronic pain acceptance and pain related self-efficacy. At 12 months the 253 
intervention arm showed continued beneficial effects on depression and social integration. These changes in 254 
health related quality of life were reflected in an incremental gain in QALYs of 0.035, a gain that was similar 255 
in size to that observed in other patient self-management programmes [41-42], and the intervention did not 256 
result in any adverse events.  The intervention was also relatively low cost, resulting in a mean costs of 257 
£5,786 ($8,521) per QALY. There is uncertainty around the estimates of costs and QALYs but when we took 258 
account of this uncertainty the intervention was shown to have a high probability (87%) of being cost 259 
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effective at the current UK National Institute for Health and Care threshold of £30,000 ($44,183) per QALY 260 
[43].   261 
 262 
The finding of a long term effect on the secondary outcome of depression is of some interest. Nearly half our 263 
participants 322/703 (46%) met the criterion for possible clinical depression at baseline [44].Our observed 264 
overall effect size on depressive symptoms exceeds the effect size found in an individual patient data meta-265 
analysis of selective serotonin reuptake inhibitors for mild/moderate depression (SMD 0.11,  95% CI −0.18 to 266 
0.41), or severe depression (SMD 0.17, 95% CI −0.08 to 0.43) [45].  267 
 268 
An exploratory post-hoc analysis found a clinically significant, sustained, improvement in depressive 269 
symptoms at 12 months amongst participants with depressive symptoms at baseline; with no benefit for 270 
those who did not meet this criterion. In these post hoc analyses the SMD gain from our intervention in the 271 
group meeting the depression criterion (-0.50, 95% CI -0.74 to -0.25) is of a similar size to those reported in a 272 
network meta-analysis of large trials (≥50 per group) of psychotherapeutic  interventions for depression [46]; 273 
Interpersonal therapy -0.73 (-1.14 to 0.32); cognitive behavioural therapy -0.47 (-0.80 to -0.35), or problem 274 
solving therapy  -0.46 (-0.81 tp-0.12); and in that reported in a Cochrane review of tricyclic antidepressants 275 
in primary care (-0.49, 95% CI -0.67 to -0.32) [47]. Notwithstanding these promising results the COPERS 276 
intervention cannot be recommended for people with depressive symptoms associated with musculoskeletal 277 
pain without evidence that this effect is found in a study including only those with depressive symptoms. 278 
 279 
The key strengths of this study were its pragmatic design, the lack of attrition and robustness of the results. 280 
We used multiple imputation to include all participants with follow-up data in the analysis, and conducted 281 
extensive sensitivity analyses to confirm the robustness of our results. Before we analysed the trial outcome 282 
we evaluated the fidelity of our intervention-this showed that it was delivered as intended [30]. 283 
 284 
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All outcomes in both intervention and control groups improved over time (Tables 2 and 3). The inclusion of a 285 
relaxation CD and leaflet along with usual care in the control arm might have reduced the apparent 286 
effectiveness of the intervention. We chose the relaxation package because other studies had suggested that 287 
although relaxation was popular it was unlikely to have an effect on our primary outcome of pain related 288 
disability or have long term effects, but we cannot exclude the possibility that it had a therapeutic effect 289 
[15].  290 
 291 
It not clear why participants in the intervention group were prescribed more pain killers than those in the 292 
control arm.  This finding might have arisen as a result of their gaining greater confidence or skill in 293 
communicating with their health professionals (an explicit aim of the intervention). The COPERS intervention 294 
could be more effective if it was combined with an intervention which attempted to optimise analgesic 295 
prescribing for each individual (a strategy we are currently investigating in chronic headache 296 
http://www2.warwick.ac.uk/fac/med/research/hscience/ctu/trials/other/chess/). 297 
 298 
A review and meta-analysis of mediation studies of people with back and neck pain found evidence that self-299 
efficacy, psychological distress and fear (principally fear of movement) may explain the development of 300 
disability in people with low back or neck pain [48], although the studies were noted to be of low quality.  In 301 
our study improvements in self-efficacy and psychological distress were not accompanied by a reduction in 302 
self-reported pain related disability. It is possible that our intervention was too brief to have an effect on 303 
pain outcomes in this population who, overall, reported a long history of pain, high levels of pain related 304 
disability and low quality of life at baseline; but we were able to demonstrate a sustained effect on 305 
psychological outcomes. Most psychological interventions recognise that while improvements in pain in 306 
these patients are unlikely, improving function and well-being are paramount. Our intervention performed 307 
as well as CBT for chronic pain [49]. 308 
 309 
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Improving pain related disability may require more intensive exercise based interventions, whilst this 310 
intervention was devised to encourage behaviour change for long term lifestyle change. Using this type of 311 
intervention as an adjunctive treatment may be optimal, for example with a stepped care analgesic 312 
algorithm, as for example in the SCOPE trial [50]. 313 
 314 
Although this brief intervention appears to be inexpensive and safe, and had a good uptake and low 315 
attrition, it did not improve the primary outcome of pain related disability.  The intervention’s potential to 316 
improve the psychological wellbeing of people with chronic pain, many of whom may also be anxious or 317 
depressed, could potentially benefit large numbers of people with chronic pain, but requires further 318 
research. Currently it is difficult to justify its use for those without depression and we do not know its 319 
effectiveness if only people with probable depression are included in the groups. 320 
 321 
Conclusion 322 
This novel, theoretically based intervention did not improve pain related disability in people with chronic 323 
musculoskeletal pain.  It may have a valuable role in promoting psychological well-being amongst people 324 
with chronic pain who are also anxious or depressed, but this needs further research.  Moreover, effective 325 
interventions to improve hard to shift outcomes, such as disability, in chronic pain patients are still required.326 
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